KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationInvestment in Debt & EquityLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Inovio Pharmaceuticals (INO) Investment in Debt & Equity (2020 - 2025)

Inovio Pharmaceuticals' Investment in Debt & Equity history spans 6 years, with the latest figure at $2.5 million for Q3 2025.

  • For Q3 2025, Investment in Debt & Equity fell 5.62% year-over-year to $2.5 million; the TTM value through Sep 2025 reached $2.5 million, down 5.62%, while the annual FY2024 figure was $1.6 million, 41.95% down from the prior year.
  • Investment in Debt & Equity for Q3 2025 was $2.5 million at Inovio Pharmaceuticals, down from $3.1 million in the prior quarter.
  • Across five years, Investment in Debt & Equity topped out at $3.9 million in Q2 2021 and bottomed at $1.6 million in Q4 2024.
  • The 5-year median for Investment in Debt & Equity is $2.6 million (2024), against an average of $2.8 million.
  • The largest annual shift saw Investment in Debt & Equity tumbled 48.62% in 2022 before it soared 40.61% in 2023.
  • A 5-year view of Investment in Debt & Equity shows it stood at $3.9 million in 2021, then crashed by 48.62% to $2.0 million in 2022, then surged by 38.52% to $2.8 million in 2023, then crashed by 41.95% to $1.6 million in 2024, then soared by 54.65% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Investment in Debt & Equity are $2.5 million (Q3 2025), $3.1 million (Q2 2025), and $2.3 million (Q1 2025).